Organization | Catalan Institute of Oncology

Catalan Institute of Oncology Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial

2017

NCT02834637

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Catalan Institute of Oncology

Active Ingredients

Drugs in Phase 3 Trials (2)

hpv 16/18 vaccine (Cervarix) (1 trial)

human papillomavirus 9-valent vaccine, recombinant (Gardasil 9) (1 trial)

Drugs in Phase 2 Trials (5)

citalopram (celexa) (1 trial)

fluorouracil (efudex) (1 trial)

foxy-5 (1 trial)

leucovorin (1 trial)

oxaliplatin (eloxatin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Colonic Neoplasms (Phase 2)

Papilloma (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 3
# of Trial APIs: 7